
Middle East and Africa Gene Expression Market Report and Forecast 2024-2032
Description
Middle East and Africa Gene Expression Market Report and Forecast 2024-2032
Middle East and Africa Gene Expression Market Report and Forecast 2024-2032
Middle East and Africa Gene Expression Market Size
The global gene expression market was valued at USD 13.3 billion in 2023, with the Middle East and Africa holding a significant market share. The market is driven by the increased government initiatives and funding in genomic research. It is expected to grow at a CAGR of 10.42% during the forecast period of 2024-2032, with the values likely to attain USD 32.4 billion by 2032.
Middle East and Africa Gene Expression Market Outlook
- Recent data reveals that around 22,000 people in Saudi Arabia die from the four main non-communicable diseases every year, accounting for 35% of all deaths in the Kingdom of Saudi Arabia. This rising disease burden is likely to augment the demand for gene expression tools and services.
- One of the major Middle East and Africa gene expression market trends is the increased government initiatives and funding to stimulate research and innovation in the genomics sector. In January 2024 , the Saudi Arabian government launched the National Biotech Strategy, intending to give the highest priority to genomics, among 4 other cutting-edge areas.
- The market share is also impacted by the rising healthcare expenditure, which often leads to increased funding for genomics and gene expression studies. For instance, under Vision 2030 , the Saudi Arabian government is planning to invest more than USD 65 billion towards the development of the country’s healthcare infrastructure and health services.
The market involves the analysis, manipulation, or measurement of gene expression patterns within cells or tissues. It comprises a range of products, technologies, and services aimed at studying gene expression. Several pharmaceutical and biotechnology companies are increasingly utilizing gene expression analysis in biomarker identification and drug discovery to develop novel drugs. Moreover, the growing demand for personalized medicine and targeted therapies is expected to drive the Middle East and Africa gene expression market growth in the forecast period.
The market Is also influenced by the increasing burden of non-communicable diseases in the region, which takes a significant toll on mortality and morbidity. Recent data reveals that around 22,000 people in Saudi Arabia die from the four main non-communicable diseases (cardiovascular diseases, cancer, diabetes , and chronic respiratory diseases) every year, accounting for 35% of all deaths in the Kingdom of Saudi Arabia. Additionally, more than 1 in 4 people are suffering from one of the 4 main non-communicable diseases, indicating the need for effective treatment options. Gene expression analysis is integral to understanding disease progression, prognosis, and treatment response as well as plays a key role in drug discovery and development. Consequently, the rising disease burden is likely to augment the Middle East and Africa gene expression market demand.
One of the major market trends is the increased government initiatives and fundings to stimulate research and innovation in the genomics sector. In January 2024 , the Saudi Arabian government launched the National Biotech Strategy as part of the project Vision 2030, with the aim to make the Kingdom of Saudi Arabia a leading biotech hub in the Middle East and Africa by 2030 and a global biotech leader by 2040. The strategy plans to give the highest priority to genomics, among 4 other cutting-edge areas, to fuel genomic research and foster advancement in precision and individualized medicine. Such rigorous government support is anticipated to boost the Middle East and Africa gene expression market share.
The market is also impacted by the rising healthcare expenditure, which often leads to increased funding for biomedical research, including genomics and gene expression studies. For instance, under Vision 2030 , the Saudi Arabian government is planning to invest more than USD 65 billion towards the development of the country’s healthcare infrastructure and health services. Such substantial investments are poised to elevate the market value in the coming years. Further, the rising foreign investment in the region by the leading market players is expected to accelerate the market growth.
Middle East and Africa Gene Expression Market Segmentation
The report offers a detailed analysis of the market based on the following segments:
Market Breakup by Technology
- Polymerase Chain Reaction
- Next Generation Sequencing
- Microarrays
- Northern Blotting
- Others
Consumables and Reagents
Instruments
Services
Market Breakup by End User
Drug Discovery and Development Centres
Diagnostic Laboratories
Academic Research Centers
Others
Market Breakup by Country
- Saudi Arabia
- United Arab Emirates
- Nigeria
- South Africa
- Others
The key features of the market report include patent analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Thermo Fisher Scientific Inc.
- Bio-Rad Laboratories
- Illumina, Inc.
- QIAGEN
- F. Hoffmann-La Roche Ltd.
- REVVITY
- PacBio
- Agilent Technologies, Inc.
- Sysmex Corporation
- BGI
- Eurofins Scientific SE
FAQs
- What is the Middle East and Africa gene expression market forecast outlook for 2024-2032?
- What are the major factors aiding the Middle East and Africa gene expression market demand?
- What are the major Middle East and Africa gene expression market trends?
- What is the market segmentation based on technology?
- What is the market breakup by product type?
- What are the major end users of the gene expression market?
- What is the market segmentation by countries?
- Who are the key players involved in the Middle East and Africa gene expression market?
Meta description
The Middle East and Africa gene expression market is poised for growth, driven by the expansion of the global market, which was valued at USD 13.3 billion in 2023 and is projected to grow at a CAGR of 10.42% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Middle East and Africa Gene Expression Market Overview
- 3.1 Middle East and Africa Gene Expression Market Historical Value (2017-2023)
- 3.2 Middle East and Africa Gene Expression Market Forecast Value (2024-2032)
- 4 Middle East and Africa Gene Expression Market Landscape*
- 4.1 Middle East and Africa Gene Expression: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Middle East and Africa Gene Expression: Product Landscape
- 4.2.1 Analysis by Technology
- 4.2.2 Analysis by Product Type
- 5 Middle East and Africa Gene Expression Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Analysis
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Middle East and Africa Gene Expression Market Segmentation (2017-2032)
- 6.1 Middle East and Africa Gene Expression Market (2017-2032) by Technology
- 6.1.1 Market Overview
- 6.1.2 Polymerase Chain Reaction
- 6.1.3 Next Generation Sequencing
- 6.1.4 Microarrays
- 6.1.5 Northern Blotting
- 6.1.6 Others
- 6.2 Middle East and Africa Gene Expression Market (2017-2032) by Product Type
- 6.2.1 Market Overview
- 6.2.2 Instruments
- 6.2.3 Reagents and Consumables
- 6.2.4 Services
- 6.3 Middle East and Africa Gene Expression Market (2017-2032) by End User
- 6.3.1 Market Overview
- 6.3.2 Drug Discovery & Development Centers
- 6.3.3 Diagnostic Laboratories
- 6.3.4 Academic Research Centers
- 6.3.5 Others
- 6.4 Middle East and Africa Gene Expression Market (2017-2032) by Countries
- 6.4.1 Market Overview
- 6.4.2 Saudi Arabia
- 6.4.3 United Arab Emirates
- 6.4.4 Nigeria
- 6.4.5 South Africa
- 6.4.6 Others
- 7 Saudi Arabia Gene Expression Market (2017-2032)
- 7.1 Saudi Arabia Gene Expression Market (2017-2032) by Technology
- 7.1.1 Market Overview
- 7.1.2 Polymerase Chain Reaction
- 7.1.3 Next Generation Sequencing
- 7.1.4 Microarrays
- 7.1.5 Northern Blotting
- 7.1.6 Others
- 7.2 Saudi Arabia Gene Expression Market (2017-2032) by Product Type
- 7.2.1 Market Overview
- 7.2.2 Instruments
- 7.2.3 Reagents and Consumables
- 7.2.4 Services
- 7.3 Saudi Arabia Gene Expression Market (2017-2032) by End User
- 7.3.1 Market Overview
- 7.3.2 Drug Discovery & Development Centers
- 7.3.3 Diagnostic Laboratories
- 7.3.4 Academic Research Centers
- 7.3.5 Others
- 8 United Arab Emirates Gene Expression Market (2017-2032)
- 8.1 United Arab Emirates Gene Expression Market (2017-2032) by Technology
- 8.1.1 Market Overview
- 8.1.2 Polymerase Chain Reaction
- 8.1.3 Next Generation Sequencing
- 8.1.4 Microarrays
- 8.1.5 Northern Blotting
- 8.1.6 Others
- 8.2 United Arab Emirates Gene Expression Market (2017-2032) by Product Type
- 8.2.1 Market Overview
- 8.2.2 Instruments
- 8.2.3 Reagents and Consumables
- 8.2.4 Services
- 8.3 United Arab Emirates Gene Expression Market (2017-2032) by End User
- 8.3.1 Market Overview
- 8.3.2 Drug Discovery & Development Centers
- 8.3.3 Diagnostic Laboratories
- 8.3.4 Academic Research Centers
- 8.3.5 Others
- 9 Nigeria Gene Expression Market (2017-2032)
- 9.1 Nigeria Gene Expression Market (2017-2032) by Technology
- 9.1.1 Market Overview
- 9.1.2 Polymerase Chain Reaction
- 9.1.3 Next Generation Sequencing
- 9.1.4 Microarrays
- 9.1.5 Northern Blotting
- 9.1.6 Others
- 9.2 Nigeria Gene Expression Market (2017-2032) by Product Type
- 9.2.1 Market Overview
- 9.2.2 Instruments
- 9.2.3 Reagents and Consumables
- 9.2.4 Services
- 9.3 Nigeria Gene Expression Market (2017-2032) by End User
- 9.3.1 Market Overview
- 9.3.2 Drug Discovery & Development Centers
- 9.3.3 Diagnostic Laboratories
- 9.3.4 Academic Research Centers
- 9.3.5 Others
- 10 South Africa Gene Expression Market (2017-2032)
- 10.1 South Africa Gene Expression Market (2017-2032) by Technology
- 10.1.1 Market Overview
- 10.1.2 Polymerase Chain Reaction
- 10.1.3 Next Generation Sequencing
- 10.1.4 Microarrays
- 10.1.5 Northern Blotting
- 10.1.6 Others
- 10.2 South Africa Gene Expression Market (2017-2032) by Product Type
- 10.2.1 Market Overview
- 10.2.2 Instruments
- 10.2.3 Reagents and Consumables
- 10.2.4 Services
- 10.3 South Africa Gene Expression Market (2017-2032) by End User
- 10.3.1 Market Overview
- 10.3.2 Drug Discovery & Development Centers
- 10.3.3 Diagnostic Laboratories
- 10.3.4 Academic Research Centers
- 10.3.5 Others
- 11 Regulatory Framework
- 12 Funding and Investment Analysis
- 12.1 Analysis by Funding Instances
- 12.2 Analysis by Type of Funding
- 12.3 Analysis by Funding Amount
- 12.4 Analysis by Leading Players
- 12.5 Analysis by Leading Investors
- 12.6 Analysis by Geography
- 13 Partnership and Collaborations Analysis
- 13.1 Analysis by Partnership Instances
- 13.2 Analysis by Type of Partnership
- 13.3 Analysis by Leading Players
- 13.4 Analysis by Geography
- 14 Supplier Landscape
- 14.1 Market Share by Top 5 Companies
- 14.2 QIAGEN
- 14.2.1 Financial Analysis
- 14.2.2 Product Portfolio
- 14.2.3 Demographic Reach and Achievements
- 14.2.4 Mergers and Acquisitions
- 14.2.5 Certifications
- 14.3 Quest Diagnostics, Inc.
- 14.3.1 Financial Analysis
- 14.3.2 Product Portfolio
- 14.3.3 Demographic Reach and Achievements
- 14.3.4 Mergers and Acquisitions
- 14.3.5 Certifications
- 14.4 F. Hoffmann-La Roche Ltd.
- 14.4.1 Financial Analysis
- 14.4.2 Product Portfolio
- 14.4.3 Demographic Reach and Achievements
- 14.4.4 Mergers and Acquisitions
- 14.4.5 Certifications
- 14.5 Illumina, Inc.
- 14.5.1 Financial Analysis
- 14.5.2 Product Portfolio
- 14.5.3 Demographic Reach and Achievements
- 14.5.4 Mergers and Acquisitions
- 14.5.5 Certifications
- 14.6 PerkinElmer, Inc.
- 14.6.1 Financial Analysis
- 14.6.2 Product Portfolio
- 14.6.3 Demographic Reach and Achievements
- 14.6.4 Mergers and Acquisitions
- 14.6.5 Certifications
- 14.7 Bio-Rad Laboratories
- 14.7.1 Financial Analysis
- 14.7.2 Product Portfolio
- 14.7.3 Demographic Reach and Achievements
- 14.7.4 Mergers and Acquisitions
- 14.7.5 Certifications
- 14.8 Thermo Fisher Scientific, Inc.
- 14.8.1 Financial Analysis
- 14.8.2 Product Portfolio
- 14.8.3 Demographic Reach and Achievements
- 14.8.4 Mergers and Acquisitions
- 14.8.5 Certifications
- 14.9 Agilent Technologies
- 14.9.1 Financial Analysis
- 14.9.2 Product Portfolio
- 14.9.3 Demographic Reach and Achievements
- 14.9.4 Mergers and Acquisitions
- 14.9.5 Certifications
- 14.10 GE Healthcare
- 14.10.1 Financial Analysis
- 14.10.2 Product Portfolio
- 14.10.3 Demographic Reach and Achievements
- 14.10.4 Mergers and Acquisitions
- 14.10.5 Certifications
- 14.11 Promega Corp.
- 14.11.1 Financial Analysis
- 14.11.2 Product Portfolio
- 14.11.3 Demographic Reach and Achievements
- 14.11.4 Mergers and Acquisitions
- 14.11.5 Certifications
- 14.12 Luminex Corp.
- 14.12.1 Financial Analysis
- 14.12.2 Product Portfolio
- 14.12.3 Demographic Reach and Achievements
- 14.12.4 Mergers and Acquisitions
- 14.12.5 Certifications
- 14.13 Takara Bio, Inc.
- 14.13.1 Financial Analysis
- 14.13.2 Product Portfolio
- 14.13.3 Demographic Reach and Achievements
- 14.13.4 Mergers and Acquisitions
- 14.13.5 Certifications
- 15 Middle East and Africa Gene Expression Market – Distribution Model (Additional Insight)
- 15.1 Overview
- 15.2 Potential Distributors
- 15.3 Key Parameters for Distribution Partner Assessment
- 16 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 17 Company Competitiveness Analysis (Additional Insight)
- 17.1 Very Small Companies
- 17.2 Small Companies
- 17.3 Mid-Sized Companies
- 17.4 Large Companies
- 17.5 Very Large Companies
- 18 Payment Methods (Additional Insight)
- 18.1 Government Funded
- 18.2 Private Insurance
- 18.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.